Navigation Links
Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
Date:10/28/2008

- Data Presentation at 48th ICAAC / IDSA 46th Annual Meeting -

PRINCETON, N.J. and ANNAPOLIS, Md., Oct. 28 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX), a leading monoclonal antibody company, and PharmAthene, Inc. (NYSE: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a pilot study showing that the anthrax anti-toxin, Valortim(R) (MDX-1303), enhanced survival as compared to a control group in a therapeutic animal model known as the New Zealand White (NZW) rabbit model. Valortim is a fully human monoclonal antibody generated by Medarex's UltiMAb(R) technology that is being co-developed by the two companies for potential use as an anti- toxin therapeutic to prevent and treat inhalation anthrax.

The data were presented in an oral presentation entitled "Therapeutic Efficacy of MDX-1303, an Anti-toxin Monoclonal Antibody, for Inhalation Anthrax in the New Zealand White (NZW) Rabbit Model" at the 48th ICAAC/ IDSA 46th Annual Meeting by Israel Lowy, M.D., Ph.D., Senior Director of Clinical Science and Infectious Diseases at Medarex.

David P. Wright, President & Chief Executive Officer of PharmAthene, commented, "Mounting evidence from a number of animal studies suggests that Valortim may be efficacious as both a prophylactic and therapeutic for inhalation anthrax infection. Based on these results, we believe that Valortim is ideally positioned for procurement consideration in the Strategic National Stockpile,
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... CA (PRWEB) December 17, 2014 ... today that it has entered into a technology ... Company (ADM) to apply DNA2.0’s proprietary protein engineering ... engineering process. , “We are extremely excited that ... engineering platform. This proprietary bioengineering technology has ...
(Date:12/17/2014)... SAN FRANCISCO, Calif. , Dec. 17, 2014 ... results of a Phase 2 study evaluating the ... the treatment of patients with severe, chronic itch ... current standard of care, including topical steroids and ... was percent change in Visual Analog Scale (VAS) ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
(Date:12/13/2014)... Maryland (PRWEB) December 12, 2014 Clarassance, ... today announced its new name: Therabron Therapeutics , ... therapy and bronchioles (a type of structure in the ... the company’s mission to develop novel protein therapeutics for ... of directors decided to change the name to mark ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... and ST. LOUIS, June 27, 2011 Verenium Corporation ... company focused on the development and commercialization of high-performance ... animal and human nutrition and health products, today announced ... suite of new enzyme products from Verenium,s late-stage product ...
... and LONDON, June 26, 2011 The pharmaceutical industry spent less ... last three years, according to data released today from the ... a Thomson Reuters business. Key highlights from the ... 21 new molecular entities (NMEs) were launched on the global market ...
... 2011 Selexis SA is a Swiss-based ... engineering of high yield and stable mammalian cell lines ... announced today it will be showcasing the new Selexis ... free SURE variant Screening at the 2011 BIO ...
Cached Biology Technology:Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 2Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 3Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 4Verenium and Novus International Inc. Announce Agreement to Develop and Commercialize Animal Nutrition Enzymes 5Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 2Drug Dropout in Clinical Trials Is at Unsustainable Levels, According to Thomson Reuters, CMR International 3Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011 2Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011 3
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
(Date:12/5/2014)... , Dec. 4, 2014 Increased emphasis ... investments in new testing and inspection technologies. The ... rise to a range of innovative test solutions. ... of Generation Y, which is generally more inclined ... result, product development strategies of test equipment vendors ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Center will use IBM technologies to advance research into ... most life-threatening diseases, including cancer. The Center's research will ... biologists, Dr. Jeffrey Skolnick, the Georgia Research Alliance Eminent ... million in grants from the State of Georgia, the ...
... in the cruise industry, including cruise lines, local ... society organizations - are taking proactive measures to ... preserving cruise destinations, according to a new report ... Cruise Destinations issued by Conservation International's (CI) Center ...
... the threats that farmed Atlantic salmon escapees constitute ... are concerned about farmed salmon yet heritable changes ... genetic level are largely unknown. , In new ... have found scientific evidence that farmed salmon have ...
Cached Biology News:Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 2Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 3Georgia Tech accelerates drug discovery with new IBM supercomputing cluster 4Report finds cruise industry is protecting the precious places it visits 2Report finds cruise industry is protecting the precious places it visits 3Report finds cruise industry is protecting the precious places it visits 4
Request Info...
We offer solid and solution phase peptide synthesis including a whole range of modifications. Please send the details of your peptide synthesis need to info@rpeptide.com...
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
Request Info...
Biology Products: